Jonathan Ciron

Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data

Chao Zhu, Sandra Vukusic, Tomáš Kalinčík, Guillaume Mathey et autres

BACKGROUND: Ofatumumab and ocrelizumab are widely used high-efficacy anti-CD20 therapies for relapsing-remitting multiple sclerosis (RRMS), but direct comparative evidence remains limited. We aimed to compare their effectiveness in routine clinical practice. METHODS: We conducted an observational cohort study emulating a target trial …

au, fr, cz, tr, hr, ir, es, nl, mx, be, ca, it, kw, si, mq (code pays fourni par la source)

Anti‐ CD20 Discontinuation Versus Continuation in People Aged Over 50 With Non‐Active Multiple Sclerosis

Alexia Moukhine, Fabien Rollot, Romain Casey, Nicolas Collongues et autres

OBJECTIVE: To determine whether discontinuing anti-CD20 therapy in people with relapsing-onset MS aged over 50 is associated with an increased risk of relapse, inflammatory activity, confirmed disability accrual, and serious infection compared with continuing therapy. METHODS: This observational, multicenter, retrospective cohort study …

fr, us, ca, mq (code pays fourni par la source)

French expert opinion on the long-term management of relapsing multiple sclerosis with cladribine tablets beyond year 4

Vito A. G. Ricigliano, Jonathan Ciron, Bertrand Bourre, Anne Marie Guennoc et autres

fr, ch (code pays fourni par la source)

French guidelines for the diagnosis and management of neuromyelitis optica spectrum disorder

L. Giorgi, R. Marignier, Julie Pique, H. Maurey et autres

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system, characterized by severe attacks. Optic neuritis is the most common clinical manifestation, leading to a rapid and often severe loss of vision, which is sometimes bilateral, with frequent …

fr (code pays fourni par la source)

A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosis

Naïl Benallegue, Fabien Rollot, Pietro Iaffaldano, Giuseppe Lucisano et autres

BACKGROUND: Early initiation of high-efficacy therapies (HETs) has been associated with improved disease control in pediatric-onset multiple sclerosis (POMS). However, some children remain clinically stable on low-/moderate-efficacy therapies (METs), highlighting the need for decision-support tools. OBJECTIVE: To develop a Therapeutic Escalation Score …

fr, it (code pays fourni par la source)

French NOMADMUS Cohort Overview

Thomas Roux, François-Xavier Lejeune, Romain Casey, Bertrand Audoin et autres

OBJECTIVES: Aquaporin 4-immunoglobulin G-seropositive neuromyelitis optica spectrum disorder (AQP4+NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are rare conditions with evolving diagnostic and therapeutic approaches. Our study aims to describe these evolutions in France, using data from the NOMADMUS cohort. METHODS: We …

fr, us (code pays fourni par la source)

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study

Izanne Roos, Sifat Sharmin, Dana Horakova, Eva Kubala Havrdova et autres

BACKGROUND: Ocrelizumab, a monoclonal antibody targeting CD20+ B cells, is a high-efficacy therapy for multiple sclerosis (MS). METHODS: Patients with relapse-onset MS treated with ocrelizumab, fingolimod, natalizumab or alemtuzumab for ≥6 months were identified from three registries: MSBase, OFSEP and Danish MS …

au, cz, kw, tr, gb, es, it, ca, be, lb, nl, nz, Tunisie, co, ir, om, fr, mx, dk (code pays fourni par la source)

Kappa free light chain index or oligoclonal bands testing in clinical practice for multiple sclerosis diagnosis: An algorithm comparative study

Michaël Levraut, Mikael Cohen, Delphine Sterlin, Xavier Ayrignac et autres

BACKGROUND: Limited evidence exists on how to use kappa free light chains (κFLCs) and oligoclonal bands (OCBs) in diagnosing intrathecal immunoglobulin synthesis (IgS). OBJECTIVE: To compare different algorithms to define IgS. METHODS: A retrospective analysis of the 2022 French cohort study was …

fr (code pays fourni par la source)

Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis

Antoine Gavoille, Anne Kerbrat, Gilles Edan, Emmanuelle Le Page et autres

BACKGROUND AND OBJECTIVES: The therapeutic strategy for late-onset multiple sclerosis (LOMS) with a relapsing-remitting onset remains unclear, potentially leading to underexposure to disease-modifying therapies (DMTs) compared with adult-onset multiple sclerosis (AOMS). We investigated the differences in DMT use between LOMS and AOMS …

fr, us, mq (code pays fourni par la source)

External validation and improvement of an algorithm that identifies multiple sclerosis relapses in the French national healthcare claims database

Laure Carcaillon‐Bentata, Abdelilah Abouelfath, S. Lignot-Maleyran, R. Lassalle et autres

BACKGROUND: Multiple sclerosis (MS) is a frequent neurological condition affecting young adults with acute disabling neurological episodes (relapses). MS relapses are not recorded in claims databases despite their importance for (pharmaco)epidemiological studies. This study aimed to validate and improve an algorithm identifying …

fr, mq (code pays fourni par la source)

Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study

Izanne Roos, Sifat Sharmin, Serkan Ozakbas, Raed Alroughani et autres

BACKGROUND AND OBJECTIVES: Patients aged ≥ 35 years at multiple sclerosis (MS) symptom onset with an Expanded Disability Status Scale (EDSS) score ≥ 3 within the first year are at highest risk of developing aggressive MS (EDSS ≥ 6 within 10 years). …

au, tr, kw, es, ca, lb, it, nl, pt, be, Tunisie, om, ir, fr, mq, us (code pays fourni par la source)

Diagnostic Value of the Kappa Free Light Chain Index to Distinguish MOGAD, NMOSD, and MS

Apolline Tournier, Antoine Gavoille, Julie Pique, Michaël Levraut et autres

BACKGROUND AND OBJECTIVES: The differential diagnosis between aquaporin-4-immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD), myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD), and multiple sclerosis (MS) can be complex. Kappa free light chain index (KFLC-Index) emerged as an effective biomarker for distinguishing patients …

fr (code pays fourni par la source)